OTCMKTS:PVCT Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis $0.05 0.00 (-2.60%) As of 01:04 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Provectus Biopharmaceuticals Stock (OTCMKTS:PVCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PVCT alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.05▼$0.0652-Week Range$0.04▼$0.08Volume8,028 shsAverage Volume73,819 shsMarket Capitalization$20.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Provectus Biopharmaceuticals, Inc. is a biotechnology company focused on developing investigational treatments for cancer and other serious diseases. The company’s primary program is PV-10, an injectable formulation of rose bengal disodium designed for intratumoral treatment of solid tumors. PV-10 has been studied for potential use in cancers including metastatic melanoma and other tumors. Provectus has also researched PH-10, an investigational topical formulation intended to stimulate immune responses in certain dermatological conditions. The company’s development approach has centered on using its proprietary formulations to activate or enhance the body’s immune response against diseased cells. Based in Knoxville, Tennessee, Provectus has historically conducted research and clinical-development activities in the United States and has explored potential applications for its technology in international markets. The company’s drug candidates remain investigational and are not approved as commercial therapies. Information about its current operations and leadership is limited, so no additional leadership details are included here.AI Generated. May Contain Errors. Read More Receive PVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVCT Stock News HeadlinesVisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company ShowcaseJuly 22, 2026 | globenewswire.comIndependent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same DoseJuly 7, 2026 | globenewswire.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 16 at 1:00 AM | Weiss Ratings (Ad)Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular InfectionsJune 30, 2026 | globenewswire.comProvectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)June 25, 2026 | globenewswire.comProvectus Shareholders Approve Reverse Stock Split AuthorityJune 22, 2026 | tipranks.comProvectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call TranscriptJune 18, 2026 | seekingalpha.comProvectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of StockholdersJune 8, 2026 | globenewswire.comSee More Headlines PVCT Stock Analysis - Frequently Asked Questions How have PVCT shares performed this year? Provectus Biopharmaceuticals' stock was trading at $0.0550 at the beginning of the year. Since then, PVCT shares have decreased by 11.5% and is now trading at $0.0487. How do I buy shares of Provectus Biopharmaceuticals? Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Provectus Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Provectus Biopharmaceuticals investors own include Cisco Systems (CSCO), Intel (INTC), Palantir Technologies (PLTR), Plug Power (PLUG), Tonix Pharmaceuticals (TNXP), Exela Technologies (XELA) and Amprius Technologies (AMPX). Company Calendar Today10/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:PVCT Previous SymbolNYSEMKT:PVCT CIK315545 Webwww.provectusbio.com Phone(866) 594-5999Fax866-998-0005Employees4Year Founded2002Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.43 million Net MarginsN/A Pretax Margin-9,731.04% Return on EquityN/A Return on Assets-599.37% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual Sales$340 thousand Price / Sales60.20 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-2.44Miscellaneous Outstanding Shares420,280,000Free Float335,383,000Market Cap$20.47 million OptionableNot Optionable Beta0.91 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:PVCT) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PVCT Stock Alerts